These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 18494606)

  • 1. A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy.
    Dinoso JB; Kim SY; Siliciano RF; Blankson JN
    Clin Infect Dis; 2008 Jul; 47(1):102-4. PubMed ID: 18494606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy.
    Bailey JR; Lassen KG; Yang HC; Quinn TC; Ray SC; Blankson JN; Siliciano RF
    J Virol; 2006 May; 80(10):4758-70. PubMed ID: 16641269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating monocytes are not a major reservoir of HIV-1 in elite suppressors.
    Spivak AM; Salgado M; Rabi SA; O'Connell KA; Blankson JN
    J Virol; 2011 Oct; 85(19):10399-403. PubMed ID: 21795348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effector mechanisms in HIV-1 infected elite controllers: highly active immune responses?
    Blankson JN
    Antiviral Res; 2010 Jan; 85(1):295-302. PubMed ID: 19733595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors.
    Gandhi SK; Siliciano JD; Bailey JR; Siliciano RF; Blankson JN
    J Virol; 2008 Mar; 82(6):3125-30. PubMed ID: 18077705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Murine Viral Outgrowth Assay to Detect Residual HIV Type 1 in Patients With Undetectable Viral Loads.
    Metcalf Pate KA; Pohlmeyer CW; Walker-Sperling VE; Foote JB; Najarro KM; Cryer CG; Salgado M; Gama L; Engle EL; Shirk EN; Queen SE; Chioma S; Vermillion MS; Bullock B; Li M; Lyons CE; Adams RJ; Zink MC; Clements JE; Mankowski JL; Blankson JN
    J Infect Dis; 2015 Nov; 212(9):1387-96. PubMed ID: 25883388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cell dynamics and the response to HAART in a cohort of HIV-1-infected elite suppressors.
    Sedaghat AR; Rastegar DA; O'Connell KA; Dinoso JB; Wilke CO; Blankson JN
    Clin Infect Dis; 2009 Dec; 49(11):1763-6. PubMed ID: 19857162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors.
    Blankson JN; Bailey JR; Thayil S; Yang HC; Lassen K; Lai J; Gandhi SK; Siliciano JD; Williams TM; Siliciano RF
    J Virol; 2007 Mar; 81(5):2508-18. PubMed ID: 17151109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
    Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The distribution of viral blips observed in HIV-1 infected patients treated with combination antiretroviral therapy.
    Percus JK; Percus OE; Markowitz M; Ho DD; Di Mascio M; Perelson AS
    Bull Math Biol; 2003 Mar; 65(2):263-77. PubMed ID: 12675332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV controllers with different viral load cutoff levels have distinct virologic and immunologic profiles.
    Côrtes FH; Passaes CP; Bello G; Teixeira SL; Vorsatz C; Babic D; Sharkey M; Grinsztejn B; Veloso V; Stevenson M; Morgado MG
    J Acquir Immune Defic Syndr; 2015 Apr; 68(4):377-385. PubMed ID: 25564106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy.
    Riddler SA; Aga E; Bosch RJ; Bastow B; Bedison M; Vagratian D; Vaida F; Eron JJ; Gandhi RT; Mellors JW;
    J Infect Dis; 2016 Feb; 213(4):556-60. PubMed ID: 26333941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outbreaks of genital herpes: effects on plasma HIV type 1 viral loads in individuals receiving highly active antiretroviral therapy.
    Lee V; Foley E; Barton SE; Patel R
    J Infect Dis; 2004 Dec; 190(11):2057-8. PubMed ID: 15529276
    [No Abstract]   [Full Text] [Related]  

  • 15. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
    Achenbach CJ; Till M; Palella FJ; Knoll MD; Terp SM; Kalnins AU; Murphy RL
    HIV Med; 2005 Jan; 6(1):7-12. PubMed ID: 15670246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 DNA proviral load in treated and untreated HIV-1 seropositive patients.
    Re MC; Vitone F; Biagetti C; Schiavone P; Alessandrini F; Bon I; de Crignis E; Gibellini D
    Clin Microbiol Infect; 2010 Jun; 16(6):640-6. PubMed ID: 19732081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recovery of viremic control after superinfection with pathogenic HIV type 1 in a long-term elite controller of HIV type 1 infection.
    Rachinger A; Navis M; van Assen S; Groeneveld PH; Schuitemaker H
    Clin Infect Dis; 2008 Dec; 47(11):e86-9. PubMed ID: 18947331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors.
    Bradney AP; Scheer S; Crawford JM; Buchbinder SP; Montefiori DC
    J Infect Dis; 1999 May; 179(5):1264-7. PubMed ID: 10191234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling the time course of CD4 T-lymphocyte counts according to the level of virologic rebound in HIV-1-infected patients on highly active antiretroviral therapy.
    Kousignian I; Abgrall S; Duval X; Descamps D; Matheron S; Costagliola D;
    J Acquir Immune Defic Syndr; 2003 Sep; 34(1):50-7. PubMed ID: 14501793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low frequency of GB virus C viremia in a cohort of HIV-1-infected elite suppressors.
    Blankson JN; Klinzman D; Astemborski J; Thomas DL; Kirk GD; Stapleton JT
    AIDS; 2008 Nov; 22(17):2398-400. PubMed ID: 18981782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.